Table 3.
Clinicopathological characteristics of the two types of DNA mismatch repair-deficient (MLH1/PMS2 and MSH2/MSH6 losses) and -proficient endometrial carcinomas.
| Variable | MLH1/PMS2 (1) | MSH2/MSH6 (2) | MMRp (3) | P (1 vs. 2) | P (1 vs 3) | P (2 vs. 3) |
|---|---|---|---|---|---|---|
| n | 50 | 66 | 196 | |||
| Age (y); median (95% CI) | 64.1 (60.67–65.56) | 61.2 (59.22–65.52) | 63.1 (61.9–63.8) | 0.62* | 0.73* | 0,74* |
| Family history of cancer | ||||||
| no | 37 (78.7%) | 36 (56.2%) | 134 (74.4%) | 0.05** | 0.54** | 0.007** |
| yes | 10 (21.2%) | 28 (40.7%) | 46 (25.5%) | |||
| Body Mass Index; median (95%CI) | 31.2 (29.5–32.6) | 31 (28.8–33.8) | 30.4 (29.7–31.6) | 0.46* | 0.34* | 0.05* |
| Histological type: | ||||||
| Endometrioid | 45 (90%) | 57 (86.4%) | 148 (75.5%) | 0.55** | 0.03** | 0.06** |
| Non-endometrioid | 5 (10%) | 9 (13.6) | 48 (24.5%) | |||
| FIGO stage | ||||||
| I/II | 28 (56%) | 53 (80.3%) | 139 (70.9%) | 0.005** | 0.04** | 0.14** |
| III/IV | 22 (44%) | 13 (19.7%) | 57 (29.1%) | |||
| ESMO-ESGO-ESTRO risk stratification | ||||||
| low | 10 (20%) | 28 (42.4%) | 59 (30.1%) | 0.007** | 0.14** | 0.02** |
| intermediate | 2 (4%) | 3 (4.5%) | 29 (14.8%) | |||
| High-intermediate | 6 (12%) | 9 (13.6%) | 12 (6.1%) | |||
| High | 20 (60%) | 24 (36.4%) | 91 (46.4%) | |||
| Advanced/metastatic | 2 (4%) | 2 (3%) | 5 (2.6%) | |||
| Low tumor grade | 36 (72%) | 49 (74.2%) | 137 (69.9%) | 0.78** | 0.50** | 0.77** |
| High tumor grade | 14 (28%) | 17 (25.8%) | 59 (30.1%) | |||
| Tumor size (cm); median (95% CI) | 4.5 (4–5.2) | 3.9 (3.4–4.4) | 4 (3.7–4.5) | 0.01* | 0.06* | 0.20* |
| Tumor size | ||||||
| ≤2.0 cm | 5 (11.1%) | 8 (13.3%) | 27 (15.3%) | 0.73** | 0.48** | 0.71** |
| >2.0 cm | 40 (88.9%) | 52 (86.7%) | 150 (84.7%) | |||
| Not evaluated | 5 | 6 | 19 | |||
| Myometrial invasion | ||||||
| <50% | 19 (38%) | 42 (63.6%) | 109 (55.9%) | 0.006** | 0.02** | 0.27** |
| ≥50% | 31 (62%) | 24 (36.4%) | 86 (44.1%) | |||
| LVSI | ||||||
| No/focal | 31 (62%) | 53 (80.3%) | 162 (83.1%) | 0.03** | 0.001 | 0.61** |
| Multifocal | 19 (38%) | 13 (19.7%) | 33 (16.9%) | |||
| MELF | ||||||
| Absent | 36 (72%) | 53 (80.3%) | 132 (67.7%) | 0.30** | 0.56** | 0.05** |
| Present | 14 (28%) | 13 (19.7%) | 63 (32.3%) | |||
| Node | ||||||
| Negative | 33 (66%) | 55 (85.9%) | 154 (61.8%) | 0.012** | 0.06** | 0.20** |
| Positive | 17 (34%) | 9 (14.1%) | 42 (21.4%) | |||
| Not evaluated | 0 | |||||
LVSI: lymphovascular space invasion; MELF: microcystic, elongated, and fragmented.
*t-test; **Chi-square test, for p-values analyzing the three groups together, see text.